CIRCIO HOLDING ASA SHARE CAPITAL INCREASE REGISTERED FOLLOWING EXERCISE OF WARRANTS AND UNDERWRITTEN PRIVATE PLACEMENT

Oslo, 18 June 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA (OSE: CRNA) (the "Company" or "Circio") on 9 June 2026 regarding (i) the results of the exercise period for the warrants (Nw.: frittstående tegningsretter) with ISIN NO0013711523 (the "Warrants") and (ii) a private placement of new shares at a subscription price of NOK 8.2508 per share directed at such underwriters as described therein (the "Underwritten Private Placement").

The exercise of the Warrants resulted in the issuance of 25,781,827 new shares (the "Warrants Shares") in the Company, and the Underwritten Private Placement resulted in the issuance of 10,578,283 new shares (the "Private Placement Shares", and together with the Warrants Shares, the "New Shares").

The share capital increases pertaining to the issuance of the New Shares is now registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). Following the registration, the Company's new registered share capital is NOK 164,719,483.20, divided into 274,532,472 shares, each with a nominal value of NOK 0.60.

The New Shares are expected to be delivered to the shareholders on or about 19 June 2026.

This information is subject to the disclosure requirements pursuant to the Continuing Obligations and Section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com

Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com

For more information regarding the Warrant Program, please contact: Pareto Securities AS Phone: +47 24 13 39 19 Email: online@paretosec.no

About Circio Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.